Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
== History == In the 19th century, the mass-to-charge ratios of some ions were measured by electrochemical methods. The first attempt to measure the mass-to-charge ratio of cathode ray particles, assuming them to be ions, was made in 1884-1890 by German-born British physicist Arthur Schuster. He put an upper limit of 10^10 coul/kg, but even that resulted in much greater value than expected, so little credence was given to his calculations at the time. In 1897, the mass-to-charge ratio of the electron was first measured by J. J. Thomson. By doing this, he showed that the electron was in fact a particle with a mass and a charge, and that its mass-to-charge ratio was much smaller than that of the hydrogen ion H+. In 1898, Wilhelm Wien separated ions (canal rays) according to their mass-to-charge ratio with an ion optical device with superimposed electric and magnetic fields (Wien filter). In 1901 Walter Kaufman measured the increase of electromagnetic mass of fast electrons (Kaufmann–Bucherer–Neumann experiments), or relativistic mass increase in modern terms. In 1913, Thomson measured the mass-to-charge ratio of ions with an instrument he called a parabola spectrograph. Today, an instrument that measures the mass-to-charge ratio of charged particles is called a mass spectrometer.
October 5–10, 1908 - The rapidly growing, global industry and scientific quest for absolute zero led to the 1st International Congress of Refrigeration held in Paris, France, at the Paris-Sorbonne University, which welcomed over 5,000 participants. January 25, 1909 - From this first Congress, the International Association of Refrigeration was born, formed by delegates from 35 countries. June 21, 1920 - The association was reorganised and officially titled as the International Institute of Refrigeration – IIR (Institut International du Froid – IIF, in French). IIR's status as an international organisation was defined by an International Agreement signed on December 1, 1954, and General Regulations for the Application of the International Agreements signed on November 20, 1956. Since then, the IIR has been operating at its headquarters based in Paris and is now an international organisation for expertise on refrigeration. The institute has continued to run the International Congress of Refrigeration every four years since its inauguration and has now expanded its event portfolio to ten conference series covering a wide variety of refrigeration topics. Working alongside governments, today the IIR remains committed to promoting knowledge on refrigeration for sustainable development, and continues to provide key services to disseminate information on associated technologies to all stakeholders (companies, universities, professionals, etc.).
Special Forces received a severe damage to its reputation when in July 1969 Colonel Robert Rheault, Commander of 5th Special Forces Group (Airborne), six subordinate military intelligence officers, attached to MACVSOG's Project GAMMA Operational Detachment B-57 including his headquarters staff intelligence officer, and a sergeant first class (SFC) were arrested for the murder of Thai Khac Chuyen, a suspected North Vietnamese double agent. It was suspected that Chuyen was providing the North Vietnamese Army information about Project GAMMA and the indigenous agents used by the 5th Special Forces Group. Thai Khac Chuyen's name was found on captured documents recovered from a MACV-SOG recon mission in Laos. An attempted cover-up was uncovered when the SFC became concerned that he might be a 'fall guy' and contacted the local Central Intelligence Agency (CIA) office chief. In September 1969 Secretary of the Army Stanley Resor announced that all charges would be dropped since the CIA, in the interests of national security, had refused to make its personnel available as witnesses; implying some sort of involvement.
140A Command and Control Systems Integrator 140K Air And Missile Defense (AMD) Tactician 140L Air and Missile Defense (AMD) Technician (Patriot Systems Technician) 140Z Air Defense Artillery (ADA) Immaterial Enlisted
Sources: en.wikipedia.org
=== Pharmacodynamics === Speciociliatine has found to be a ligand of the mu and kappa opioid receptors, however findings are varied as to whether it functions as an agonist or a competitive antagonist at those sites.
== Short-term regulation of hunger and food intake == Short-term regulation of hunger and food intake involves neural signals from the GI tract, blood levels of nutrients, GI tract hormones, and psychological factors.
== Mobile phase == The mobile phase, or the liquid phase that runs across the column during separation, for HILIC is typically composed of a high amount of water-miscible, polar organic solvent and a low amount of water. Typically, acetonitrile ("MeCN", also designated as "ACN") is used for the organic solvent, though other aprotic water-miscible solvents, such as alcohols at higher concentration, tetrahydrofuran, or dioxane, can also be used. As with other methods of chromatography, the mobile phase can be delivered isocratically or with a gradient starting at high-organic progressing towards increasing aqueous content. If using a mobile phase gradient, the mobile phase will progressively increases in polar-aqueous content, causing increasingly polar analytes to be eluted. All ions partition into the stationary phase to some degree, so an occasional "wash" with water is required to ensure a reproducible stationary phase.
This means that simple preparations are developed initially for use in phase I clinical trials. These typically consist of hand-filled capsules containing a small amount of the drug and a diluent. Proof of the long-term stability of these formulations is not required, as they will be used (tested) in a matter of days. Consideration has to be given to what is known as "drug loading" - the ratio of the active drug to the total contents of the dose. A low drug load may cause homogeneity problems. A high drug load may pose flow problems or require large capsules if the compound has a low bulk density. By the time phase III clinical trials are reached, the formulation of the drug should have been developed to be close to the preparation that will ultimately be used in the market. A knowledge of stability is essential by this stage, and conditions must have been developed to ensure that the drug is stable in the preparation. If the drug proves unstable, it will invalidate the results from clinical trials since it would be impossible to know what the administered dose actually was. Stability studies are carried out to test whether temperature, humidity, oxidation, or photolysis (ultraviolet light or visible light) have any effect, and the preparation is analysed to see if any degradation products have been formed.
=== Stepwise Assembly === More complex cage architectures often require stepwise assembly strategies. This approach involves the systematic construction of cage fragments followed by their controlled combination into the final structure. While more time-consuming, stepwise assembly offers greater control over the final product and is particularly useful for asymmetric cage structures. The key advantage of this method lies in its ability to isolate and characterize intermediate products, ensuring the quality of each synthetic step. For instance, in the synthesis of large cages, building blocks can be first combined into smaller sub-cages or fragments, which are then purified before final assembly. This strategy is particularly valuable when working with expensive or sophisticated building blocks, as it minimizes material waste and allows for optimization of each step.
Sources: en.wikipedia.org
QICC cable factory in Doha Lulu Hypermarket in Dibba Oryx Metal industries in Oman Cooling plant for Dubai Metro TAKREER research center in Abu Dhabi Cast house and offices for EMAL Solar field assembly for Shams solar power station Emirates SkyCargo Terminal Phase 1 of the Dubai Design District (D3) IKEA Distribution Center - Dubai Nestle Dubai Manufacturing Inbound Warehouse for Almarai in Al Kharj Fruit Cold Store for Del Monte Foods in Khorma Warehouse and Offices for RSA Logistics in Dubai Logistics City US$160m Food Plant for BRF S.A. in Abu Dhabi Presidential Flights Hangar 2 at Abu Dhabi International Airport ADNOC Accommodations in Ruwais by DuBox RSA Cold Chain Facility in Dubai South Light Industrial Units for Jebel Ali Free Zone Authority
Freeze-dried nanocellulose aerogels used in sanitary napkins, tampons, diapers or as wound dressing The use of nanocellulose as a composite coating agent in cosmetics e.g. for hair, eyelashes, eyebrows or nails A dry solid nanocellulose composition in the form of tablets for treating intestinal disorders Nanocellulose films for screening of biological compounds and nucleic acids encoding a biological compound Filter medium partly based on nanocellulose for leukocyte free blood transfusion A buccodental formulation, comprising nanocellulose and a polyhydroxylated organic compound Powdered nanocellulose has also been suggested as an excipient in pharmaceutical compositions Nanocellulose in compositions of a photoreactive noxious substance purging agent Elastic cryo-structured gels for potential biomedical and biotechnological application Matrix for 3D cell culture
NAD+ loss is followed by depletion of ATP, defects in mitochondrial movement and depolarization, calcium influx, externalization of phosphatidylserine, and loss of membrane permeability prior to catastrophic axonal self-destruction. SARM1 activation due to loss of NMNAT2 in neurons also elicits a pro-degenerative neuroinflammatory response from peripheral nervous system macrophages and central nervous system astrocytes and microglia.
=== Jonah Atterbury === Jonah Atterbury (Kal Penn) is the co-founder and CEO of Tender, which he started with his college friend Whitney Halberstram. Once an ambitious business school graduate, Jonah has since devolved into an irresponsible and inattentive CEO, addicted to partying, drugs, and pornography, and frequently showing up intoxicated to the office. He clashes with Whitney over the latter's desire to pivot Tender away from lucrative "alternative merchants" like porn and gambling and towards banking. Whitney and the Tender board soon use behavioral clauses in Jonah's contract to remove him as CEO, citing his inappropriate behavior, poor hygiene, and misuse of company funds; Whitney takes over in the interim. Jonah is later contacted by Sweetpea Golightly, who is investigating Tender's shady finances as part of a short; a vengeful Jonah, who is suing Whitney for defamation, emails Sweetpea a trove of subpoenaed internal Tender emails that she uses to uncover a connection to Accra. After Tender's stock plummets following revelations of its fraud, Whitney attempts to contact Jonah, who rebuffs him.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.